Hydrogel material for retroperitoneal tumor operation wound repair and recurrence prevention
The hydrogel formed by combining materials such as thiolated gelatin and oxidized sodium alginate has solved the problems of difficult wound healing and recurrence after retroperitoneal tumor resection, and has achieved rapid hemostasis, repair and continuous anti-tumor treatment.
Patent Information
- Application Number
- CN202511086058.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-08-05
- Publication Date
- 2025-11-04
AI Technical Summary
Existing materials cannot effectively solve the problems of difficult wound healing and tumor recurrence after retroperitoneal tumor resection. Traditional hemostatic materials lack anti-tumor activity, local chemotherapy drug delivery systems have insufficient adhesion, and commercially available anti-adhesion membranes are difficult to adhere to irregular wounds.
A hydrogel material is formed by combining a matrix phase composed of thiolated gelatin, sodium alginate oxide, polyvinyl alcohol and carboxymethyl chitosan, a functional phase composed of drug-loaded nanoparticles and recombinant human collagen, and an auxiliary phase composed of calcium chloride, glutaraldehyde, graphene oxide and vitamin E succinate, to achieve rapid gelation and sustained drug release.
It achieves rapid hemostasis of tumor wounds and rapid repair of large wounds, reduces postoperative adhesions, and continuously inhibits tumor cells through the sustained release of drug-loaded nanoparticles, thereby reducing the risk of recurrence.